Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096974 · ClinicalTrials.gov registry record · Phase 1
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
A Phase 1 study of Advanced Solid Tumors, sponsored by Shanghai YingLi Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06096974 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Shanghai YingLi Pharmaceutical Co.. The registered enrollment target is 60 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06096974, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Shanghai YingLi Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
Conditions Studied
Interventions
- DRUG YL-17231
Study Locations (3)
Ohio
- The Lindner Center for Research & Education at The Christ Hospital - Cincinnati
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute and Hospital, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096974
The ClinicalTrials.gov registry entry for NCT06096974 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (70% lower). The listed sponsor is Shanghai YingLi Pharmaceutical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which YL-17231 is the first listed.
NCT06096974 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT06096974 about?
NCT06096974 is a clinical study titled "Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS". This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
What is the current status of trial NCT06096974?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-10-24. Estimated completion is 2026-04.
What conditions does trial NCT06096974 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06096974?
The interventions under investigation include: YL-17231 (DRUG).
Who is sponsoring clinical trial NCT06096974?
This trial is sponsored by Shanghai YingLi Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096974 being conducted?
This trial has 3 study locations across Ohio, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.